

21 May 2026

## Spinal Muscular Atrophy (SMA)

I have a freedom of information request related to the diagnosis and treatment of Spinal Muscular Atrophy.

1. **How many patients have a current diagnosis for Spinal Muscular Atrophy (ICD-10 Code G12.0, G12.1, G12.8 and G12.9) at your Trust?**

There are currently eleven patients with a diagnosis of SMA.

2. **How many patients have been treated in the last 4 months (January to April 2026) with the following products:**

- **Evrysdi (Risdiplam)**

**If available, please provide the split of the number of patients treated with Evrysdi (Risdiplam) by TABLET and SOLUTION formulations.**

There are currently five patients treated with Risdiplam Solution.

- **Spinraza (Nusinersen)**

There are currently <5 patients treated with Nusinersen.

**Use of <5 (less than five):** We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - Personal Information relating to a third party, as the small numbers involved could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

- **Zolgensma (Onasemnogene)**

Zero

3. **How many new patients\* have been treated in the last 4 months (January to April 2026) with the following products:**

- **Evrysdi (Risdiplam)**

**If available, please provide the split of the number of patients treated with Evrysdi (Risdiplam) by TABLET and SOLUTION formulations.**

- **Spinraza (Nusinersen)**

- **Zolgensma (Onasemnogene)**

***\*New patients are defined as patients who were not treated with any of Spinraza (Nusinersen), Evrysdi (Risdiplam) or Zolgensma (Onasemnogene) in the previous 4-month period (September to December 2025).***

There have been no new patients in the last 4 months.

21 May 2026

4. **Of the total patients treated in the last 4 months (January to April 2026) with Evrysdi (Risdiplam), please provide the number of patients that were treated with Spinraza (Nusinersen) in the previous 4 months (September to December 2025).**

*If available, please provide the split of the number of patients treated with Evrysdi (Risdiplam) by TABLET and SOLUTION formulations.*

There were <5 patients treated with Nusinersen.

5. **Of the total patients treated in the last 4 months (January to April 2026) with Zolgensma (Onasemnogene), please provide the number of patients that were treated with Spinraza (Nusinersen) in the previous 4 months (September to December 2025).**

There were <5 patients treated with Nusinersen.

Again, we are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - Personal Information relating to a third party

6. **Of the total patients treated in the last 4 months (January to April 2026) with Spinraza (Nusinersen), please provide the number of patients that were treated with Evrysdi (Risdiplam) in the previous 4 months (September to December 2025).**

There were five patients treated with Risdiplam.